The World’s Most Comprehensive Microbial CDMO Ecosystem
Elise Biopharma operates the world’s most extensive portfolio of microbial manufacturing platforms—more than one hundred rigorously qualified hosts across bacteria, yeasts, filamentous fungi, actinomycetes, cyanobacteria, and extremophiles. This breadth is not window dressing; it’s a deliberate architecture that lets programs move fluidly between chassis as the science demands. Whether a molecule needs the raw productivity of E. coli, the secretory finesse of Komagataella/Pichia, the glyco-competence of yeast, the secondary-metabolite power of Streptomyces, or the stress tolerance of halophiles and thermophiles, the platform exists, is validated, and is ready to scale.
Where others specialize narrowly, Elise builds bridges between hosts and disciplines—recombinant protein production, metabolic pathway engineering, probiotic and live biotherapeutic formulation, phage and VLP biology—under one coherent scientific and quality framework. Two core hubs anchor this ecosystem: Cambridge, Massachusetts, for advanced method development, high-throughput design of experiments, and regulatory-facing analytics; and Montréal, Canada, for industrial-scale fermentation, downstream innovation, and fill–finish integration. The result is a connected, bicoastal North American engine that unifies strain engineering, PAT-driven upstream control, chromatography and membrane DSP, and dossier-ready QC—so programs don’t stall when biology refuses to fit a template.
Every organism in our library is an industrial chassis—sequenced, characterized, and process-validated for use in cGMP or hybrid production. Together, these hosts form a living catalogue of options: aerobic or anaerobic, thermophilic or psychrophilic, secretory or intracellular. This diversity enables rational host selection based on molecule class, regulatory path, and economic target.
Our Microbial Platforms framework integrates three pillars:
- Expression control: tuning transcription, translation, and secretion to the molecule’s physicochemical needs.
- Process intelligence: AI-assisted fermentation, PAT-driven feeding, and digital twin scale-up.
- Analytical certainty: harmonized QC pipelines that align across hosts and modalities.
Whether developing an industrial enzyme, a live biotherapeutic, or a novel lipid metabolite, Elise Biopharma provides the infrastructure and expertise to transform microbial diversity into manufacturing certainty.
1. Industrial Protein & Enzyme Platforms
E. coli CDMO Services – The global workhorse for recombinant proteins. Rapid growth, high titers, cost efficiency, and mature regulatory precedent.
Bacillus subtilis CDMO Services – GRAS-status secretion system ideal for enzymes and postbiotic proteins; excellent for detergent, feed, and diagnostic enzymes.
Komagataella phaffii (Pichia pastoris) – High-density yeast host with eukaryotic folding and secretory precision; proven for mAbs fragments and glycoproteins.
Saccharomyces cerevisiae – Classic yeast for vaccines, nutraceuticals, and Fc-fusion constructs; extensive clinical heritage.
Yarrowia lipolytica – Lipid-metabolizing yeast optimized for hydrophobic proteins, biosurfactants, and fatty-acid conjugates.
Corynebacterium glutamicum – Amino-acid secretion specialist and robust cell-factory chassis for biochemicals.
Streptomyces spp. – Natural product and complex enzyme producer; modular PKS/NRPS machinery for secondary metabolites.
Aspergillus niger & Trichoderma reesei – Filamentous fungi for industrial enzymes, cellulases, and food-grade proteins.
Bacillus licheniformis – Thermostable enzyme source with strong GRAS and feed additive credentials.
Value lever: highest yield per unit cost, scalable secretion, and regulatory familiarity.
2. Metabolic & Chemical Synthesis Platforms
Designed for bio-based chemicals, solvents, and specialty organics.
Clostridium acetobutylicum – Anaerobic ABE (acetone–butanol–ethanol) fermentation master; model for solventogenic processes.
Corynebacterium metabolite systems – Amino-acid and organic-acid synthesis; tolerant to industrial stress.
Zymomonas mobilis – Ethanol producer with low biomass and high productivity; now extended to lactate and succinate.
Gluconobacter oxydans – Incomplete oxidation catalyst; ideal for vitamin C intermediates and rare sugars.
Halomonas spp. – Salt-tolerant chassis enabling non-sterile continuous fermentation and cost-cutting process intensification.
Cupriavidus necator – CO₂-fixing platform for polyhydroxyalkanoate (PHA) bioplastics and sustainable materials.
Aspergillus oryzae & Rhodococcus opacus – Metabolic versatility for aromatics and specialty metabolites.
Propionibacterium freudenreichii – Propionic-acid producer with food-grade status.
Geobacillus stearothermophilus – Thermophilic enzyme factory; reduces contamination risk through elevated process temperature.
Value lever: green chemistry, solvent tolerance, circular-carbon feedstocks.
3. Lipid, Pigment & Fragrance Platforms
High-value molecules for food, beauty, and wellness.
Y. lipolytica (lipid pathways) – Engineered for omega-3, squalene, and cocoa-butter analogs.
Mortierella alpina – Rich arachidonic-acid source with nutraceutical validation.
Schizochytrium spp. – DHA and EPA powerhouse used in vegan omega-oil production.
Monascus spp. – Natural pigment and cholesterol-lowering secondary metabolite producer.
Rhodotorula & Blakeslea trispora – Carotenoid and β-carotene factories for cosmetics and food colorants.
Value lever: sustainable pigment and lipid production replacing petrochemical analogs.
4. Probiotic & Microbiome Platforms
For live biotherapeutics, nutraceuticals, and microbiome research.
Lactobacillus spp. – Core probiotic genus; diverse metabolic and pH-tolerance profiles.
Bifidobacterium spp. – Anaerobic commensals for gut-immune modulation; demanding culture requirements mastered at Elise.
Akkermansia muciniphila – Next-generation gut strain with metabolic benefits; cultivated under mucin-based simulation.
Faecalibacterium prausnitzii – Anti-inflammatory but oxygen-sensitive; handled in fully anaerobic systems.
Bacillus coagulans – Spore-forming probiotic stable at ambient temperature; ideal for shelf-stable formulations.
Saccharomyces boulardii – Eukaryotic probiotic yeast used in gastrointestinal therapies.
Lactococcus lactis & Enterococcus faecium – Food-grade vectors for mucosal vaccine and peptide delivery.
Value lever: CFU stability, encapsulation technology, and GMP anaerobic culture.
5. Phage & Gene Editing Platforms
Therapeutic phages, VLPs, and CRISPR toolkits.
Bacteriophage CDMO Services – GMP propagation and purification under high-containment conditions.
Listeria & Pseudomonas Phages – Targeted antimicrobial agents for food safety and clinical use.
CRISPR Bacteria CDMO Services – Plasmid and Cas-delivery systems for gene-editing applications.
VLP Yeast Platforms – Virus-like-particle expression for vaccine and diagnostics.
Value lever: sterility, host-range validation, and rapid vectorization workflows.
6. Extremophile & Thermostable Platforms
Biotech for the edge of life.
Thermus thermophilus & Pyrococcus furiosus – Sources of thermostable polymerases and enzymes.
Sulfolobus solfataricus & Halobacterium spp. – Acidic and halophilic hosts for specialty enzymes.
Deinococcus radiodurans – Radiation-resistant bacterium for space and defense biotech.
Methanococcus maripaludis – Archaea for methane and hydrogen bioconversion.
Value lever: enzyme discovery for high-temperature, high-pressure, or defense environments.
7. Phototrophic & Algal Platforms
Harnessing sunlight and carbon dioxide.
Synechocystis & Anabaena – Model cyanobacteria for CO₂ fixation and photosynthetic bioproduction.
Spirulina (Arthrospira) – Protein-rich food and feed microalga.
Chlamydomonas reinhardtii & Scenedesmus obliquus – Genetic model algae for pigment and hydrogen generation.
Value lever: solar bioreactors, bioplastics precursors, sustainable pigments.
8. Anaerobic & Gas Fermentation Platforms
Turning waste gases into value.
Clostridium ljungdahlii & Moorella thermoacetica – C1-gas fermenters converting CO and H₂ into ethanol or acetate.
Acetobacterium woodii & Sporomusa ovata – Electrosynthetic bacteria for power-to-chemicals pathways.
Geobacter sulfurreducens – Electricity-producing biofilm organism bridging biology and energy.
Value lever: carbon capture and e-fuel bioconversion.
9. Environmental & Agricultural Platforms
Microbes that repair ecosystems and sustain agriculture.
Rhizobium & Bradyrhizobium – Nitrogen-fixing symbionts for biofertilizers.
Azospirillum & Paenibacillus – Plant-growth promoters and biofilm stabilizers.
Bacillus thuringiensis – Bioinsecticide producer with long regulatory history.
Shewanella oneidensis – Metal-reducing bacterium for remediation and biosensing.
Value lever: carbon-negative agriculture, biopesticides, and soil health.
10. Synthetic & Consortia Platforms
Engineered communities and digital-twin biofoundries.
Pseudomonas putida – Synthetic-biology chassis with solvent tolerance.
Acinetobacter baylyi – Naturally competent bacterium ideal for genetic circuits.
Bacillus megaterium & Rhodococcus spp. – Large-cell factories for biopolymers and biosurfactants.
Zymomonas mobilis ZM4 & Caldicellulosiruptor – Model organisms for cellulose conversion and hybrid consortia.
Value lever: modular plasmid systems, adaptive control, and AI-orchestrated consortia.
Digital Integration & Data Continuity
Every microbial platform at Elise Biopharma operates within a unified digital ecosystem. Process data—feeding curves, metabolite profiles, QC results—flows seamlessly across hosts, creating a comparative intelligence layer. This allows clients to pivot between E. coli and Yarrowia, or between anaerobic and aerobic systems, without restarting development.
Our electronic batch records (21 CFR Part 11) and QbD-aligned analytics deliver real-time visibility from bench to pilot. This cross-species data integration is what differentiates Elise’s Microbial Platforms program from traditional siloed CDMOs.
Global Compliance & Sustainability
All microbial operations follow ISO 9001, 13485, and cGMP frameworks, supported by validated containment and environmental systems.
Feedstocks are sourced from renewable supply chains; waste biomass is valorized through enzyme recovery or biofertilizer conversion.
Our microbial expertise directly supports ESG goals—reducing carbon intensity while enabling circular bioeconomy production.
Conclusion — The Living Infrastructure of Biomanufacturing
Microbes built civilization—from bread to penicillin—and now they are building its sustainable future.
Elise Biopharma’s Microbial Platforms embody that continuum: 100 industrial hosts, each optimized, documented, and digitally integrated.
This ecosystem is not a catalog; it is a strategy.
By aligning strain biology with regulatory insight and data infrastructure, we convert microbial diversity into manufacturable reality.
Whether your vision lies in therapeutic proteins, next-generation probiotics, green chemistry, or synthetic ecosystems, our microbial portfolio provides the chassis, the analytics, and the confidence to make it tangible.
Email our team directly at info@elisebiopharma.com